Enrolling by invitationNCT07503613
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Studying Vestibular schwannoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Akouos, Inc.
- Principal Investigator
- Aaron Tward, MDEli Lilly and Company
- Enrollment
- 100 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2040
Study locations (1)
- University of Texas Southwestern, Dallas, Texas, United States
Collaborators
Eli Lilly and Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07503613 on ClinicalTrials.govOther trials for Vestibular schwannoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07364955Vestibular Rehabilitation Protocol in Unilateral Vestibular SchwannomaAlbert Torrents Torrero
- ACTIVE NOT RECRUITINGNANCT07130851Mapping of Vestibular Centers Activation Using fMRI in Patients With Vestibular SchwannomaMarketa Bonaventurova
- RECRUITINGNANCT06660082Early Rehabilitation Using Head Impulse Test for Acute Vestibular DeficitHospices Civils de Lyon
- RECRUITINGPHASE1, PHASE2NCT06517888Anti-VEGF Gene Therapy Trial for Vestibular SchwannomaAkouos, Inc.
- RECRUITINGNANCT06572475USPIO Enhanced MR Imaging in CNS Tumours (UMIC)Northern Care Alliance NHS Foundation Trust
- RECRUITINGNANCT06112509Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife Radio-surgeryCentre Hospitalier Universitaire de Besancon
- RECRUITINGNANCT05702749Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular SchwannomasMedical College of Wisconsin
- RECRUITINGNCT05641441Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular SchwannomaUniversity Hospital, Geneva